



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/623,914	07/21/2003	Thomas M. Hering	27708/04065	5367
24024	7590	06/11/2007	EXAMINER	
CALFEE HALTER & GRISWOLD, LLP			DUNSTON, JENNIFER ANN	
800 SUPERIOR AVENUE			ART UNIT	PAPER NUMBER
SUITE 1400			1636	
CLEVELAND, OH 44114				
MAIL DATE		DELIVERY MODE		
06/11/2007		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/623,914	HERING ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Jennifer Dunston	1636	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) Responsive to communication(s) filed on 20 March 2007.
- 2a) This action is **FINAL**.                    2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) Claim(s) 8-14 and 35-37 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) Claim(s) 8-13 and 36 is/are allowed.
- 6) Claim(s) 14 and 35 is/are rejected.
- 7) Claim(s) 37 is/are objected to.
- 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on 20 March 2007 is/are: a) accepted or b) objected to by the Examiner.  
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All    b) Some \* c) None of:
  1. Certified copies of the priority documents have been received.
  2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- |  |  |
|--|--|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)                     | 4) <input type="checkbox"/> Interview Summary (PTO-413)                  |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ .   |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)          | 5) <input type="checkbox"/> Notice of Informal Patent Application        |
| Paper No(s)/Mail Date _____ .  | 6) <input checked="" type="checkbox"/> Other: <u>Exhibits I and II</u> . |

## **DETAILED ACTION**

This action is in response to the amendment, filed 3/20/2007, in which claims 1-7 and 15-34 were canceled, claims 8-14 were amended, and claims 35-37 were newly added. Currently, claims 8-14 and 35-37 are pending.

Applicant's arguments have been thoroughly reviewed, but are not persuasive for the reasons that follow. Any rejections and objections not reiterated in this action have been withdrawn. **This action is FINAL.**

### *Election/Restrictions*

Applicant elected Group without traverse in the reply filed on 8/11/2006. Claims 8-14 and 35-37 are currently under consideration.

### *Specification*

The disclosure is objected to because of the following informalities:

The specification indicates that the sequence presented in Figure 6 is disclosed in SEQ ID NO: 4 and is encoded by SEQ ID NO: 3 (e.g. paragraphs [0031 and [0056]). However, the sequence of SEQ ID NO: 3 does not encode the sequence of SEQ ID NO: 4 (see the attached alignment in Exhibit I).

Appropriate correction is required. This is a new objection, necessitated by the amendment to the sequence listing in the reply filed 3/20/2007.

***Claim Objections***

Claim 14 is objected to because of the following informalities: the word “and” should be placed before item (b) in the Markush-type group to conform to the accepted language. One acceptable form of alternative expression, which is commonly referred to as a Markush group, recites members as being “selected from the group consisting of A, B and C.” See *Ex parte Markush*, 1925 C.D. 126 (Comm'r Pat. 1925). Appropriate correction is required. This is a new objection, necessitated by the amendment of claim 14 in the reply filed 3/20/2007.

Claim 37 is objected to because of the following informalities: the verb does not agree with the subject. It would be remedial to amend the claim to replace the word “are” with the word “is” to improve the grammar of the claim. Appropriate correction is required. This is a new objection, necessitated by the addition of new claim 37 in the reply filed 3/20/2007.

***Response to Arguments - 35 USC § 112***

The rejection of claims 8-13 under 35 U.S.C. 112, second paragraph, has been withdrawn in view of Applicant's amendment to the sequence listing in the reply filed 3/20/2007.

The rejection of claims 8-12 and 14 under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement, has been withdrawn in view of Applicant's amendment to the claims in the reply filed 3/20/2007.

***Claim Rejections - 35 USC § 102***

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

- (a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

Claims 14 and 35 are rejected under 35 U.S.C. 102(a) as being anticipated by GenBank Accession No. AC011508.1 (GI: 6015244, October 7, 1999; see the entire reference). This rejection was made over claim 14 in the Office action mailed 10/18/2006. The rejection has been rewritten to address amended claim 14 and has been extended to new claim 35.

Regarding claim 14, GenBank Accession No. AC011508 teaches a polynucleotide that comprises a fragment of at least 210 nucleotides in length and is identical to a sequence within nucleotides 25-1581 of SEQ ID NO: 3 (see the alignment in Exhibit II). GenBank Accession No. AC011508.1 teaches a sequence that is at least 210 nucleotides in length and is identical to a nucleotide sequence extending from nucleotide 196 through nucleotide 521 of GenBank Accession No. AC011508.1 (see the alignment in Exhibit II).

Regarding claim 35, GenBank Accession No. AC011508 teaches a polynucleotide that comprises a fragment of at least 210 nucleotides in length and is identical to a sequence within nucleotides 163-423 of SEQ ID NO: 3 (see the alignment in Exhibit II). GenBank Accession No. AC011508.1 teaches a sequence that is at least 210 nucleotides in length and is identical to a nucleotide sequence extending from nucleotide 196 through nucleotide 521 of GenBank Accession No. AC011508.1 (see the alignment in Exhibit II).

***Response to Arguments - 35 USC § 102***

The rejection of claims 8-10, 12 and 14 under 35 U.S.C. 102(e) as being anticipated by Brennan et al (US 5,985,551) has been withdrawn in view of Applicant's amendment to the claims in the reply filed 3/20/2007.

The rejection of claims 8-12 under 35 U.S.C. 102(a) as being anticipated by GenBank Accession No. AC011508.1 (GI: 6015244, October 7, 1999) has been withdrawn in view of Applicant's amendment to the claims in the reply filed 3/20/2007. The nucleotide sequence of GenBank Accession No. AC011508.1 does not encode a protein that is at least 90% identical to the full-length sequence of SEQ ID NO: 4 and does not contain the full-length coding sequence set forth in SEQ ID NO: 3.

With respect to the rejection of claim 14 35 U.S.C. 102(a) as being anticipated by GenBank Accession No. AC011508.1 (GI: 6015244, October 7, 1999), Applicant's arguments filed 3/20/2006 have been fully considered but they are not persuasive.

The response asserts that the amendment of claim 14 to recite that the polynucleotide is at least 210 nucleotides in length and has a sequence that is identical to or complementary to a sequence extending from nucleotide 25 through nucleotide 1581 of SEQ ID NO: 3 overcomes the rejection. This is not found persuasive, because GenBank Accession No. AC011508.1 teaches a sequence that is at least 210 nucleotides in length and is identical to a nucleotide sequence extending from nucleotide 196 through nucleotide 521 of GenBank Accession No. AC011508.1 (see the alignment in Exhibit II). This sequence is more than 210 nucleotides in length.

For these reasons, and the reasons made of record in the previous office actions, the rejection is maintained.

***Conclusion***

Claims 8-13 and 36 are allowed.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jennifer Dunston whose telephone number is 571-272-2916. The examiner can normally be reached on M-F, 9 am to 5 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph Woitach can be reached on 571-272-0739. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1636

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Jennifer Dunston  
Examiner  
Art Unit 1636

/JD/

CELINE QIAN, PH.D.  
PRIMARY EXAMINER





## Blast 2 Sequences results

PubMed

Entrez

BLAST

OMIM

Taxonomy

Structure

### BLAST 2 SEQUENCES RESULTS VERSION BLASTN 2.2.16 [Mar-25-2007]

Match: 1 Mismatch: -2 gap open: 5 gap extension: 2

x\_dropoff: 0 expect: 10.000 wordsize: 11 Filter  View option Standard Masking character option X for protein, n for nucleotide  Masking color option Black  Show CDS translation Align


Sequence 1: lcl|3

SEQ ID NO:3



Length = 2143 (1 .. 2143)

Sequence 2: gi|6015244|gb|AC011508.1|AC011508

Length = 104342 (1 .. 104342)



2



1

NOTE: Bitscore and expect value are calculated based on the size of the nr database.

NOTE: If protein translation is reversed, please repeat the search with reverse strand of the query sequence.



		Score = 3698 bits (1923), Expect = 0.0 Identities = 1948/1958 (99%), Gaps = 1/1958 (0%) Strand=Plus/Plus	
Query	160	GATTTGGAGTCAAAACGTATGAGACCAAAAAATTTTCAGAAAATGATATTTTGA A	219
Sbjct	52355		52414
Query	220	ATAAATTTCAGTGGGAGATGAAGGCACAAAGTAAAACCCTGGCCTTGAGGCATCC	279
Sbjct	52415		52474
Query	280	ATCTCAGAAATAATTGGAAGTGCAAAAGCATATTGAGGGACTAAAGGACATCAAGAG	339
Sbjct	52475		52534
Query	340	GGATACTTCAGTCAAATGATAATCAGCTATGAAAAAATACCTTCTTACAGAAAAAGTAAA	399
Sbjct	52535		52594
Query	400	TCTCTTACTCCACATCAAAGAATTCTATAATACAGAGAAATCCTATGTTGTAAGGAATGT	459
Sbjct	52595		52654
Query	460	GGGAAGGCTTGCAGTCATGGCTCAAAACTTGTCAACATGAGAGAACTCATACTAGCTGAA	519
Sbjct	52655		52714
Query	520	AAGCACTTGAATGTAAAGAATGTGGGAGAATTATTAAGTGCCTATCAACTCAATGTG	579
Sbjct	52715		52774
Query	580	CATCAGAGATTCATACTGGTGAGAAACCTATGAGTGTAAAGGAATGTGGGAAGACCTTT	639
Sbjct	52775		52834
Query	640	AGCTGGGGATCAAGCCTTGTAAACATGAGAGAAATTCACACTGGTGAGAAACCTATGAA	699
Sbjct	52835		52894
Query	700	TGTAAAGAATGTGGGAGGCCTTTAGTCGTGGCTATCACCTAACCAACATCAGAAAATT	759
Sbjct	52895		52954
Query	760	CATATTGGTGTGAAATCTTATAATGTAAGGAATGTGGGAGGCCTTTGGGCTCA	819
Sbjct	52955		53014
Query	820	AGCCTTGCTAACATGAGATAATTACAGGTGAGAAACCTTATAATGTAAGAATGT	879
Sbjct	53015		53074

Query	880	GGGAAGGCCTTCAGTCGTGGCTATCAACTTACTCAGCATCAGAAAATCCATACTGGTAAG 	939
Sbjct	53075	GGGAAGGCCTTCAGTCGTGGCTATCAGCTTACTCAGCATCAGAAAATCCATACTGGTAAG 	53134
Query	940	AAACCTTATGAATGTAAAATATGTGAAAGGCTTTGTTGGGCTATCAACTTACTCGA 	999
Sbjct	53135	AAACCTTATGAATGTAAAATATGTGAAAGGCTTTGTTGGGCTATCAACTTACTCGA 	53194
Query	1000	CATCAGATATTCTACACTGGTGAGAAACCCTATGAATGCAAGGAATGTGGGAAGGCTTT 	1059
Sbjct	53195	CATCAGATATTCTACACTGGTGAGAAACCCTATGAATGCAAGGAATGTGGGAAGGCTTT 	53254
Query	1060	AATTGCGGATCAAGTCTTATTCAACATGAAAGAATTCTACACTGGTGAGAAACCTTATGAA 	1119
Sbjct	53255	AATTGCGGATCAAGTCTTATTCAACATGAAAGAATTCTACACTGGTGAGAAACCTTATGAA 	53314
Query	1120	TGTAAAGAACATGTGGAAAGGCCTTAGTCGTGGCTATCACCTTCTCAACATCAGAAAATC 	1179
Sbjct	53315	TGTAAAGAACATGTGGAAAGGCCTTAGTCGTGGCTATCACCTTCTCAACATCAGAAAATC 	53374
Query	1180	CATACTGGTGAGAAACCTTTGAATGTAAGGAATGTGGGAAGGCCTTAGTTGGGTTCA 	1239
Sbjct	53375	CATACTGGTGAGAAACCTTTGAATGTAAGGAATGTGGGAAGGCCTTAGTTGGGTTCA 	53434
Query	1240	AGCCTTGTAAACATGAGAGAGTTACACTGGTGAGAAATCCATGAATGTAAGAACATGC 	1299
Sbjct	53435	AGCCTTGTAAACATGAGAGAGTTACACTGGTGAGAAATCCATGAATGTAAGAACATGC 	53494
Query	1300	GGAAAGACCTTTGTAGTGGGTATCAACTTACTCGACATCAGGTATTCACACTGGTGAG 	1359
Sbjct	53495	GGAAAGACCTTTGTAGTGGGTATCAACTTACTCGACATCAGGTATTCACACTGGTGAG 	53554
Query	1360	AAACCCTATGAATGTAAGGAATGTGGGAAGGCTTTAATTGTGGATCAAGCCTGTTCAA 	1419
Sbjct	53555	AAACCCTATGAATGTAAGGAATGTGGGAAGGCTTTAATTGTGGATCAAGCCTGTTCAA 	53614
Query	1420	CATGAAAGAACATACAGGGGAGAAACCCTATGAATGTAAGAACATGT-GGAAGGCTTT 	1478
Sbjct	53615	CATGAAAGAACATACAGGGGAGAAACCCTATGAATGTAAGAACATGTGGGAAGGCTTT 	53674
Query	1479	AGTCGTGGCTATCACCTTACTCAACATCAGAAAATTCAACCGGTGAGAAACCTTCAA 	1538
Sbjct	53675	AGTCGTGGCTATCACCTTACTCAACATCAGAAAATTCAACCGGTGAGAAACCTTCAA 	53734
Query	1539	TGTAAGGAATGTGGGAAGGCCTTCAGTTGGGTTCAAGCCTAGTTAACATGAGAGAGTC 	1598
Sbjct	53735	TGTAAGGAATGTGGGAAGGCCTTCAGTTGGGTTCAAGCCTAGTTAACATGAGAGAGTC 	53794
Query	1599	CATACTAATGAGAACAGTCTTATGAATGTAAGACTGTGGGAAGGCCTTGGTAGTGGCTAT 	1658
Sbjct	53795	CATACTAATGAGAACAGTCTTATGAATGTAAGACTGTGGGAAGGCCTTGGTAGTGGCTAT 	53854
Query	1659	CAACTTAGTGTTCATCAGAGATTCACACTGGTGAGAAGCTTATCAACATAAGGAATT 	1718
Sbjct	53855	CAACTTAGTGTTCATCAGAGATTCACACTGGTGAGAAGCTTATCAACGTAAGGAATT 	53914
Query	1719	GGGAAGACCTTACTCGTGGCTAAAACCTGTTCATGAGAGAACTCATAGTAATGATAAA 	1778
Sbjct	53915	GGGAAGACCTTACTCGTGGCTAAAACCTGTTCATGAGAGAACTCATAGTAATGATAAA 	53974

Query	1779	CCCTACAAATATAACGAATGTGGGAAGCCTTCTGTGGACAACTTACTCAAATGAGAAA	1838
Sbjct	53975	CCCTACAAATATAACGAATGTGGGAAGCCTTCTGTGGACAACTTACTCAAATGAGAAA	54034
Query	1839	ATTGATACTGATGAAACCTTATGATTGAAAGTTGAAAAGAATATTTGTGTGCGTAT	1898
Sbjct	54035	ATTGATACTGATGAAACCTTATGATTGAAAGTTGAAAAGAATATTTGTGTGCGTAT	54094
Query	1899	AGACAACTTATCATAATAAGAACTCTTACTCTTGAGAACCTTGTGAATGTAAGGGTTGT	1958
Sbjct	54095	AGACAACTTATCATAATAAGAACTCTTACTCTTGAGAACCTTGTGAATGTAAGGGTTGT	54154
Query	1959	GCAAAAGCCATTCTATTCTGTTATGGCAATTATCTTGCTATCCAGCAATTCTACTAG	2018
Sbjct	54155	GCAAAAGCCATTCTATTCTGTTATGGCAATTATCTTGCTATCCAGCAATTCTACTAG	54214
Query	2019	TGAGAAATATTTGAATATAATTAAATATGAAAAGGCCTTAGACTCTGTACAGTCTTAT	2078
Sbjct	54215	TGAGAAATATTTGAATATAATTAAATATGAAAAGGCCTTAGACTCTGTACAGTCTTAT	54274
Query	2079	TGGATATCAATTATACTGATGTAACATTTAAATG	2116
Sbjct	54275	TGGATATCAATTATACTGATGTAACATTTAAATG	54312

---

Score = 406 bits (211), Expect = 2e-109  
 Identities = 618/819 (75%), Gaps = 1/819 (0%)  
 Strand=Plus/Plus

Query	748	CATCAGAAAATTCATATTGGTGTGAAATCTTATAATGTAAGGAATGTGGGAAGGCCTT	807
Sbjct	23822	CATCAGAAAATTCATCATGGTGTGAAACCCCTACAAATGTAAGGAATGTGGAAAGGCCTT	23881
Query	808	TTTGCGCTCAAGCCTTGTAAACATGAGATAATTCTACACAGGTGAGAACCTTATAAA	867
Sbjct	23882	GGTCATCGTTCAAGTCTTACCAACATAAGAAAATTCTGGTGAGAACCATATAAA	23941
Query	868	TGTAAAGAATGTGGGAAGGCCTTCAGTCGTGGCTATCAACTTACTCAGCATCAGAAAATC	927
Sbjct	23942	TGTGAACAATGTGAAAAGGCCTTGTTCGCAGCTATCTACTTGTGAACATCAAAGAAGT	24001
Query	928	CATACTGGTAAGAAACCTTATGAATGTAACATATGTGGAAAGGCCTTGTGGCTAT	987
Sbjct	24002	CATACTGGTGAGAACCTCATGAATGCATGGAATGTGGAAAGGCCTTGTGAAGGCCTCA	24061
Query	988	CAACTTACTCGACATCAGATATTCATACTGGTGAGAACCCATGAATGCAAGGAATGT	1047
Sbjct	24062	AGCCTTCTAACATAAGAGAATTCTAGTAGTGTGAGAACCTATGATTGTAAGGATTGT	24121
Query	1048	GGGAAGGCCTTTAATTGCGGATCAAGTCTTATTCAACATGAAAGAATTCTACTGGTGAG	1107
Sbjct	24122	GGAAAGGCCTTTGTAGAGGCTCTCAACTCACAGCATCAGAGAATTCTACTGGTGAG	24181
Query	1108	AAACCTTATGAATGTAAGAATGTGGAAAGGCCTTAGTCGTGGCTATCACCTTCTCAA	1167

## Exhibit I



## Blast 2 Sequences results

PubMed

Entrez

BLAST

OMIM

Taxonomy


Structure

## BLAST 2 SEQUENCES RESULTS VERSION BLASTP 2.2.16 [Mar-25-2007]


Matrix **BLOSUM62**  gap open: **11** gap extension: **1**x\_dropoff: **0** expect: **10.0000** wordsize: **3** Filter  View option **Standard** Masking character option **X** for protein, **n** for nucleotide  Masking color option **Black**  Show CDS translation **Align**

**Sequence 1:** lcl|SID3\_ORF      *Protein encoded by SEQ ID NO:3.*  
**Length = 517 (1 .. 517)**

**Sequence 2:** lcl|SID4      *Protein of SEQ ID NO:4.*  
**Length = 518 (1 .. 518)**



NOTE: Bitscore and expect value are calculated based on the size of the nr database.



Score = 957 bits (2475), Expect = 0.0, Method: Composition-based stats.  
 Identities = 516/517 (99%), Positives = 516/517 (99%), Gaps = 0/517 (0%)

Query 1	MTDGLVTFRDVAIDFSQEEWECLDPQAQRDLYVDVMLENSNLVSLDLESKTYETKKYFSE	60
Sbjct 1	MTDGLVTFRDVAIDFSQEEWECLDPQAQRDLYVDVMLENSNLVSLDLESKTYETKK FSE	60
Query 61	NDIFEINFSQWEMKDKSKTLGLEASIFRNNWKCKSIFEGLKGHQEGYFSQMIISYEKIPS	120
Sbjct 61	NDIFEINFSQWEMKDKSKTLGLEASIFRNNWKCKSIFEGLKGHQEGYFSQMIISYEKIPS	120
Query 121	YRKSKSLTPHQRIHNTEKSYVCCECGKACSHGSKLVQHERHTAEKHFECKECGKNYLSA	180
Sbjct 121	YRKSKSLTPHQRIHNTEKSYVCCECGKACSHGSKLVQHERHTAEKHFECKECGKNYLSA	180
Query 181	YQLNVHQRFHTGEKPYPECKECGKTFSWGSSLVKHERIHTGEKPYPECKECGKA FSRGYHLT	240
Sbjct 181	YQLNVHQRFHTGEKPYPECKECGKTFSWGSSLVKHERIHTGEKPYPECKECGKA FSRGYHLT	240

Query	241	QHQKIHIGVKSYKCKECGKAFFWGSSLAKHEIIHTGEKPYKCKECGKAFSRGYQLTQHQK	300
Sbjct	241	QHQKIHIGVKSYKCKECGKAFFWGSSLAKHEIIHTGEKPYKCKECGKAFSRGYQLTQHQK	300
Query	301	IHTGKKPYECKICGKAFCWGYQLTRHQIFHTGEKPYECCKECGKAFNCGSSLIQHERIHTG	360
Sbjct	301	IHTGKKPYECKICGKAFCWGYQLTRHQIFHTGEKPYECCKECGKAFNCGSSLIQHERIHTG	360
Query	361	EKPYECKECGKAFSRGYHLSQHQKIHTGEKPFECKECGKAFSWGSSLVKHERVHTGEKSH	420
Sbjct	361	EKPYECKECGKAFSRGYHLSQHQKIHTGEKPFECKECGKAFSWGSSLVKHERVHTGEKSH	420
Query	421	ECKECGKTFCSGYQLTRHQVFHTGEKPYECCKECGKAFNCGSSLVQHERIHTGEKPYECKE	480
Sbjct	421	ECKECGKTFCSGYQLTRHQVFHTGEKPYECCKECGKAFNCGSSLVQHERIHTGEKPYECKE	480
Query	481	CGRLLVVAITLLNIRKFIPVRNLSNVRNVGRPSVGQ	517
Sbjct	481	CGRLLVVAITLLNIRKFIPVRNLSNVRNVGRPSVGQ	517

CPU time: 0.02 user secs. 0.01 sys. secs 0.03 total secs.